ํํ ์ฐ ํด๋ฆฌ์คํ์ดํธ ๋ํธ๋ฅจ
**ํํ ์ฐ ํด๋ฆฌ์คํ์ดํธ ๋ํธ๋ฅจ(PPS)**์ ๋๋๋ฐค๋๋ฌด ํค๋ฏธ์ ๋ฃฐ๋ก์ค์ค์์ ์ถ์ถํ ๋ฐํฉ์ฑ ํคํ๋ฆฐ ์ ์ฌ ๊ณ ๋ถ์ ํ์ํ๋ฌผ ์ ๋์ฒด์ ๋๋ค. ์์ํ์์๋ ์ฃผ๋ก **๊ณจ๊ด์ ์ผ ์งํ ์ํ์ (DMOAD)** ๋ฐ ํ๋ถ ์๋ก ์งํ์ ๋ณด์กฐ ์๋ฒ์ผ๋ก ์ฌ์ฉ๋ฉ๋๋ค. ์ฃผ์ ์์ ์ ์ฉ: * **๊ณจ๊ด์ ์ผ(OA):** ๊ฐ, ๊ณ ์์ด, ๋ง์์ ๊ด์ ๊ธฐ๋ฅ ๊ฐ์ , ์ผ์ฆ ๊ฐ์ ๋ฐ ์ฐ๊ณจ ๊ฑด๊ฐ ์ฆ์ง์ ์ํด ์ฌ์ฉ๋ฉ๋๋ค. * **๊ณ ์์ด ํน๋ฐ์ฑ ํ๋ถ ์๋ก ์งํ(FLUTD) / ๊ฐ์ง์ฑ ๋ฐฉ๊ด์ผ:** ๋ฐฉ๊ด ์๋ก์ํผ์ ๋ณดํธ์ ์ธ ๊ธ๋ฆฌ์ฝ์ฌ๋ฏธ๋ ธ๊ธ๋ฆฌ์นธ(GAG) ์ธต์ ๋ณต์ํ๋ ๋ฐ ๋์์ ์ฃผ๊ธฐ ์ํด ํ๊ฐ ์ธ(off-label)๋ก ์ฌ์ฉ๋์ง๋ง, ๋จ๊ธฐ ๊ธ์ฑ ๋ฐ์์ ๋ํ ์์์ ํจ๋ฅ์ ์ ์ ์ฆ๋์ง ์์์ต๋๋ค. *์์ ํ:* ๊ตฌ์กฐ์ ์ผ๋ก ํคํ๋ฆฐ๊ณผ ์ ์ฌํ์ง๋ง ํญ์๊ณ ํ์ฑ์ ํ์ ํ ์ฝํฉ๋๋ค(ํคํ๋ฆฐ์ ์ฝ 1/15). ๊ทธ๋ฌ๋ ์ถํ์ฑ ์งํ์ด ์๊ฑฐ๋ ์์ ์ ์๋ ํ์์๊ฒ๋ ์ฌ์ ํ ์ฃผ์๊ฐ ํ์ํฉ๋๋ค.
์์ฉ ๊ธฐ์ : Pentosan polysulfate sodium exhibits multiple pharmacological effects depending on the target tissue: * **Osteoarthritis (Disease-Modifying Effects):** * **Inhibits catabolic enzymes:** Downregulates **matrix metalloproteinases (MMPs)** and **aggrecanases** that degrade articular cartilage. * **Stimulates matrix synthesis:** Promotes the synthesis of **hyaluronic acid** by synovial fibroblasts and preserves proteoglycan content within the cartilage matrix. * **Improves microcirculation:** Its mild anticoagulant, fibrinolytic, and hypolipidemic properties help mobilize thrombi and lipid deposits in subchondral blood vessels, thereby increasing synovial blood flow and nutrition to the joint. * **Interstitial Cystitis / FLUTD:** * **Urothelial Protection:** Excreted partially unchanged in the urine, PPS adheres to the mucosal membranes of the bladder wall. It acts as a synthetic **glycosaminoglycan (GAG) buffer**, preventing irritating urinary solutes and toxins from reaching and damaging the underlying transitional epithelial cells. * **Analgesia:** Provides mild local analgesic and anti-inflammatory effects within the bladder wall.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Persistent or recurrent FLUTD ยท 2-16 mg/kg PO q12h ยท PO ยท q12h ยท Recent studies have not shown any statistical benefit.
- Persistent or recurrent FLUTD ยท 8 mg/kg PO q12h ยท PO ยท q12h ยท Recent studies have not shown any statistical benefit.
- Osteoarthritis ยท 3 mg/kg IM on four occasions with an interval of 7 days between injections. ยท IM ยท q7d ยท 4 doses
- Osteoarthritis ยท Inject mixture back into joint ยท Intra-articular ยท Once ยท Prepare site as for surgery. Avoid iodine based skin preps; use neutral soapless cleanser. Withdraw ~1 mL synovial fluid, mix with pentosan in syringe, inject back. Firmly bandage and confine for 3-4 hours. Rest horse for 2 weeks, follow with 2 weeks graded walking.
- Osteoarthritis (High loading dose for treatment of OA signs of pain, lameness and stiffness) ยท 20 mg/kg PO twice weekly for 5 weeks ยท PO ยท twice weekly ยท 5 weeks ยท Always give on an empty stomach.
- Osteoarthritis (Medium Loading dose for management of OA after joint surgery) ยท 10 mg/kg PO once weekly for 12 weeks ยท PO ยท once weekly ยท 12 weeks ยท Always give on an empty stomach.
- Osteoarthritis (Maintenance dose) ยท 10 mg/kg once weekly for 4 weeks as needed ยท PO ยท once weekly ยท 4 weeks ยท Always give on an empty stomach.
- Osteoarthritis ยท 3 mg/kg IM or SC on four occasions with an interval of 5-7 days between injections ยท IM/SC ยท q5-7d ยท 4 doses
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Known hypersensitivity to pentosan polysulfate sodium
- Patients with active bleeding disorders
- Use with caution prior to surgery
์ด์๋ฐ์
- Vomiting
- Anorexia
- Lethargy
- Mild depression
- Bleeding or prolonged coagulation times (dose-dependent increase in PTT in horses)
- Transient increases in liver enzymes (reported in humans)
์ฝ๋ฌผ ์ํธ์์ฉ
- NSAIDs (e.g., carprofen, meloxicam) ยท May increase the risk of bleeding due to concurrent effects on coagulation and platelet function; use cautiously.
- Aspirin ยท Increased risk of bleeding due to combined anticoagulant and antiplatelet effects.
- Heparin ยท Additive anticoagulant effects; increased risk of hemorrhage.
๋ชจ๋ํฐ๋ง
- Clinical efficacy (improvement in lameness/mobility for OA, or reduction in urinary signs for FLUTD)
- Signs of bleeding or bruising
- Intra-articular bleeding (when administered directly into joints)
๊ณผ์ฉ๋
Information regarding overdoses is limited. * **Potential Signs:** Overdoses could potentially cause bleeding, thrombocytopenia, gastrointestinal distress, and liver function abnormalities. * **Treatment:** Treatment recommendations are basically supportive in nature. If an acute oral overdose occurs, consider standard protocols for drug removal from the gut (e.g., emesis, activated charcoal) if performed promptly.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.